Adicet Bio Inc. (ACET) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Adicet Bio Inc. (NASDAQ: ACET) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.58 (-6.04% 1D, market cap $33.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACET ranks #783 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACET carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IBO (Impact BioMedical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -27.5%, cap $33.1M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, ACET leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
Per ACET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001720580), Adicet Bio Inc. generated $0 in revenue, -$116.8M in net income, and -$97.0M in free cash flow against $192.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ACET currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.03) and Max Pain ($3.76) forces dealer call-delta covering toward $13.59.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Adicet Bio Inc. (ACET) dropped -6.04% to $3.58, trading at 3% of its 52-week range ($3.32 – $12.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
REDWOOD CITY, Calif., October 30, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune dise
REDWOOD CITY, Calif., October 22, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune dise
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACET today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACET. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Adicet Bio Inc. (ACET) ranks #783 by composite RQD confidence (32/100, grade E) and #791 by equity capitalization ($33.5M). Within this direct 5-issuer industry benchmark cohort, ACET leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. LITS currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ACET at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACET
ACTIVE
Adicet Bio Inc. | E | 32/100 | — | — | -35.0% | -6.04% | $33.5M | Benchmark Subject |
| IBO Impact BioMedical Inc. | E | 30/100 | — | -30.0% | -27.5% | -3.00% | $33.1M | /ibo-vs-acet → |
| IXHL Incannex Healthcare Inc. | D- | 37/100 | — | — | -35.0% | -4.80% | $32.4M | /ixhl-vs-acet → |
| FLNA Filana Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | +1.12% | $31.8M | /flna-vs-acet → |
| LITS Lite Strategy Inc. | D | 47/100 | — | — | -18.9% | -4.88% | $35.6M | /lits-vs-acet → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Adicet Bio Inc. (ACET) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$116.8M, operating cash flow of -$95.2M, and free cash flow of -$97.0M (-3.7% YoY). On the balance sheet, ACET closed FY2025 with $192.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$116.8M | -$95.2M | -$97.0M | $192.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$117.1M | -$92.4M | -$93.5M | $220.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$142.7M | -$93.7M | -$93.7M | — | — |
As of 2026-11-02, Adicet Bio Inc. (NASDAQ: ACET) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.58 (-6.04% 1D, market cap $33.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACET ranks #783 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACET carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IBO (Impact BioMedical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -27.5%, cap $33.1M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, ACET leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
Per ACET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001720580), Adicet Bio Inc. generated $0 in revenue, -$116.8M in net income, and -$97.0M in free cash flow against $192.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ACET last traded at $3.58 (-6.04% on volume of 176,220 shares), positioning the stock -49.08% below its 50-day simple moving average ($7.03) and -53.32% below its 200-day simple moving average ($7.67). Across its 52-week range of $3.32 to $12.94, ACET sits at the 2.7% percentile with a 14-day RSI of 22.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.13 to $4.03).
Why ACET Stock dropped -6.04% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).